Business Description
Pulmatrix Inc
NAICS : 325412
SIC : 2834
ISIN : US74584P1030
Description
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.19 | |||||
| Equity-to-Asset | 0.53 | |||||
| Debt-to-Equity | 0.49 | |||||
| Debt-to-EBITDA | -0.66 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -12.15 | |||||
| Beneish M-Score | -2.44 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -39 | |||||
| 3-Year EBITDA Growth Rate | 16 | |||||
| 3-Year EPS without NRI Growth Rate | 17.8 | |||||
| 3-Year FCF Growth Rate | 19.9 | |||||
| 3-Year Book Growth Rate | -27.3 | |||||
| Future 3-5Y Total Revenue Growth Rate | -5.24 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.32 | |||||
| 9-Day RSI | 51.08 | |||||
| 14-Day RSI | 53.35 | |||||
| 6-1 Month Momentum % | -18.5 | |||||
| 12-1 Month Momentum % | -44.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.33 | |||||
| Quick Ratio | 5.33 | |||||
| Cash Ratio | 4.9 | |||||
| Days Sales Outstanding | 42.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26.5 | |||||
| Shareholder Yield % | -45.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -201.97 | |||||
| Net Margin % | -193.49 | |||||
| FCF Margin % | -219.03 | |||||
| ROE % | -59.11 | |||||
| ROA % | -39.41 | |||||
| ROIC % | -160.97 | |||||
| ROC (Joel Greenblatt) % | -286.68 | |||||
| ROCE % | -46.81 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.98 | |||||
| PB Ratio | 0.4 | |||||
| Price-to-Tangible-Book | 0.4 | |||||
| EV-to-EBIT | 0.22 | |||||
| EV-to-EBITDA | 0.25 | |||||
| EV-to-Revenue | -0.45 | |||||
| EV-to-FCF | 0.2 | |||||
| Price-to-Net-Current-Asset-Value | 1.48 | |||||
| Price-to-Net-Cash | 2.26 | |||||
| Earnings Yield (Greenblatt) % | 454.55 | |||||
| FCF Yield % | -220.03 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers